CDX
MIA PaCa-2
Tumor indication
Pancreatic
Tumor subtype
Pancreatic Ductal Adenocarcinoma
Description
MIA PaCa-2 (Pancreatic Cancer CDX Model)
The MIA PaCa-2 line was derived from a pancreatic ductal adenocarcinoma (PDAC). It carries a KRAS mutation, common in pancreatic cancer. MIA PaCa-2 is widely applied in drug screening and biomarker studies for PDAC. Its aggressive biology and reproducibility make it a staple in pancreatic cancer research.
Key Features:
- Derived from pancreatic ductal adenocarcinoma.
- KRAS-mutant pancreatic cancer model.
- Aggressive growth phenotype.
- Tumorigenic in xenograft settings.
Applications:
MIA PaCa-2 supports therapeutic development for pancreatic cancer. Researchers use it to test chemotherapies and targeted therapies. It is applied in resistance and biomarker discovery studies. Its reproducible growth makes it a reliable PDAC research model.
Details
- Tumor indication
- Pancreatic
- Tumor subtype
- Pancreatic Ductal Adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.